EGFR and neoplasm: In these 76 patients, genomic profiling of 128 tumors by MSK-IMPACT yielded a median of 8 somatic alterations per tumor (range, 1–47), and a major oncogenic driver alteration (e.g., EGFR, KRAS, ALK, ROS1, or MET exon 14) was identified in 107 tumors (84%).